Literature DB >> 1971195

A somatostatin-secreting cell line established from a human pancreatic islet cell carcinoma (somatostatinoma): release experiment and immunohistochemical study.

H Iguchi1, I Hayashi, A Kono.   

Abstract

Production and secretion of somatostatin (SRIF) were studied using a carcinoembryonic antigen (CEA)-producing cell line (QGP-1) established from a human pancreatic islet cell carcinoma. High concentrations of SRIF (274 +/- 51 ng/mg of protein, mean +/- SD, n = 5) and CEA (3083 +/- 347 ng/mg of protein, mean +/- SD, n = 5) were present in QGP-1 cells, and the basal secretion rates of SRIF and CEA by the cells (n = 5) were 46.4 +/- 4.8 and 1690 +/- 78 pg/10(5) cells/h, respectively. Immunohistochemical studies revealed the presence of SRIF in xenografts of QGP-1 cells and colocalization of SRIF and CEA. Secretion of SRIF by QGP-1 cells was stimulated in the presence of high K+ (50 mmol) and theophylline (10 mmol), but arginine (10 mmol) and glucose (300 mg/dl) had no effect on the SRIF secretion. The QGP-1 cell line may be useful for studying the regulation mechanism of SRIF secretion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971195

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Human and Rodent Cell Lines as Models of Functional Melatonin-Responsive Pancreatic Islet Cells.

Authors:  Juliane Zibolka; Ina Bähr; Elmar Peschke; Eckhard Mühlbauer; Ivonne Bazwinsky-Wutschke
Journal:  Methods Mol Biol       Date:  2022

2.  Large-scale identification of endogenous secretory peptides using electron transfer dissociation mass spectrometry.

Authors:  Kazuki Sasaki; Tsukasa Osaki; Naoto Minamino
Journal:  Mol Cell Proteomics       Date:  2012-12-18       Impact factor: 5.911

3.  Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.

Authors:  Helma Freitag; Friederike Christen; Florentine Lewens; Irina Grass; Franziska Briest; Sara Iwaszkiewicz; Britta Siegmund; Patricia Grabowski
Journal:  Neuroendocrinology       Date:  2016-08-12       Impact factor: 4.914

4.  In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters.

Authors:  Raul M Luque; Miguel Sampedro-Nuñez; Manuel D Gahete; Ana Ramos-Levi; Alejandro Ibáñez-Costa; Esther Rivero-Cortés; Ana Serrano-Somavilla; Magdalena Adrados; Michael D Culler; Justo P Castaño; Mónica Marazuela
Journal:  Oncotarget       Date:  2015-08-14

5.  FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.

Authors:  Franziska Briest; Erika Berg; Irina Grass; Helma Freitag; Daniel Kaemmerer; Florentine Lewens; Friederike Christen; Ruza Arsenic; Annelore Altendorf-Hofmann; Almut Kunze; Jörg Sänger; Thomas Knösel; Britta Siegmund; Michael Hummel; Patricia Grabowski
Journal:  Oncotarget       Date:  2015-04-10

6.  The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.

Authors:  Tobias Hofving; Yvonne Arvidsson; Bilal Almobarak; Linda Inge; Roswitha Pfragner; Marta Persson; Göran Stenman; Erik Kristiansson; Viktor Johanson; Ola Nilsson
Journal:  Endocr Relat Cancer       Date:  2018-03       Impact factor: 5.678

7.  Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.

Authors:  Xin Zhang; Tim Zegar; Anais Lucas; Chevaun Morrison-Smith; Tatiana Knox; Christopher A French; Stefan Knapp; Susanne Müller; Jens T Siveke
Journal:  Oncogene       Date:  2020-05-04       Impact factor: 9.867

8.  A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1.

Authors:  Kim B Luley; Shauni B Biedermann; Axel Künstner; Hauke Busch; Sören Franzenburg; Jörg Schrader; Patricia Grabowski; Ulrich F Wellner; Tobias Keck; Georg Brabant; Sebastian M Schmid; Hendrik Lehnert; Hendrik Ungefroren
Journal:  Cancers (Basel)       Date:  2020-03-14       Impact factor: 6.639

9.  Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.

Authors:  Miguel Sampedro-Núñez; Raúl M Luque; Ana M Ramos-Levi; Manuel D Gahete; Ana Serrano-Somavilla; Alicia Villa-Osaba; Magdalena Adrados; Alejandro Ibáñez-Costa; Elena Martín-Pérez; Michael D Culler; Mónica Marazuela; Justo P Castaño
Journal:  Oncotarget       Date:  2016-02-09

10.  A Combination of Species Identification and STR Profiling Identifies Cross-contaminated Cells from 482 Human Tumor Cell Lines.

Authors:  Xiaocui Bian; Zhenli Yang; Hailiang Feng; Hao Sun; Yuqin Liu
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.